Pleco Therapeutics' aim is to establish the market value and therapeutic potential of our patented PlecoidTM medications by focusing first on orphan cancer treatments. Current pre-clinical development activities at the firm are focused on the development of medicines for Acute Myeloid Leukaemia (AML), a relatively rare blood cancer, andSmall-Cell Lung Cancer (SCLC), an aggressive subtype of lung cancer. Both diseases carry a poor prognosis.

Clinical Trials

Pharmaceutical

Health Care

Pleco Therapeutics BV

Ivo Timmermans

Tamara Kokaz

Rudi Jansen

Julie Powell

Callum Meikle

Gerben de Rijk

Dan Gelvan

Pleco Therapeutics BV

Org chart

Teams

Offices

Similar companies